JP2022028918A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022028918A5 JP2022028918A5 JP2021196080A JP2021196080A JP2022028918A5 JP 2022028918 A5 JP2022028918 A5 JP 2022028918A5 JP 2021196080 A JP2021196080 A JP 2021196080A JP 2021196080 A JP2021196080 A JP 2021196080A JP 2022028918 A5 JP2022028918 A5 JP 2022028918A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- ror1
- biological sample
- antibody
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 24
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims 12
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims 11
- 102100039614 Nuclear receptor ROR-alpha Human genes 0.000 claims 11
- 239000012472 biological sample Substances 0.000 claims 10
- 210000001519 tissue Anatomy 0.000 claims 10
- 108091008324 binding proteins Proteins 0.000 claims 8
- 102000023732 binding proteins Human genes 0.000 claims 8
- 238000002560 therapeutic procedure Methods 0.000 claims 6
- 230000027455 binding Effects 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 230000009870 specific binding Effects 0.000 claims 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 3
- 102000004190 Enzymes Human genes 0.000 claims 3
- 108090000790 Enzymes Proteins 0.000 claims 3
- 208000009956 adenocarcinoma Diseases 0.000 claims 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 2
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 238000011357 CAR T-cell therapy Methods 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 1
- 238000011467 adoptive cell therapy Methods 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 208000002458 carcinoid tumor Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000000975 dye Substances 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- -1 fluorescent labels Proteins 0.000 claims 1
- 102000049583 human ROR1 Human genes 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 208000000649 small cell carcinoma Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662290337P | 2016-02-02 | 2016-02-02 | |
| US62/290,337 | 2016-02-02 | ||
| US201662324876P | 2016-04-19 | 2016-04-19 | |
| US62/324,876 | 2016-04-19 | ||
| JP2018539977A JP7029401B2 (ja) | 2016-02-02 | 2017-02-02 | 抗ｒｏｒ１抗体およびその使用 |
| PCT/US2017/016300 WO2017136607A1 (en) | 2016-02-02 | 2017-02-02 | Anti-ror1 antibodies and uses thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018539977A Division JP7029401B2 (ja) | 2016-02-02 | 2017-02-02 | 抗ｒｏｒ１抗体およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022028918A JP2022028918A (ja) | 2022-02-16 |
| JP2022028918A5 true JP2022028918A5 (enExample) | 2022-06-23 |
Family
ID=58054529
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018539977A Active JP7029401B2 (ja) | 2016-02-02 | 2017-02-02 | 抗ｒｏｒ１抗体およびその使用 |
| JP2021196080A Pending JP2022028918A (ja) | 2016-02-02 | 2021-12-02 | 抗ｒｏｒ１抗体およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018539977A Active JP7029401B2 (ja) | 2016-02-02 | 2017-02-02 | 抗ｒｏｒ１抗体およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10968275B2 (enExample) |
| EP (2) | EP3411408B1 (enExample) |
| JP (2) | JP7029401B2 (enExample) |
| CN (1) | CN108699149B (enExample) |
| AU (1) | AU2017213844A1 (enExample) |
| CA (1) | CA3012827A1 (enExample) |
| ES (1) | ES2903228T3 (enExample) |
| MX (1) | MX2018009011A (enExample) |
| WO (1) | WO2017136607A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ733841A (en) | 2015-01-16 | 2024-01-26 | Juno Therapeutics Inc | Antibodies and chimeric antigen receptors specific for ror1 |
| EP3368574A1 (en) | 2015-10-30 | 2018-09-05 | NBE-Therapeutics AG | Anti-ror1 antibodies |
| CN108848669B (zh) | 2016-01-20 | 2022-06-07 | 斯克利普斯研究所 | Ror1抗体组合物和相关方法 |
| CN108699149B (zh) | 2016-02-02 | 2023-01-06 | 弗雷德哈钦森癌症中心 | 抗-ror1抗体及其用途 |
| SG11201907580SA (en) | 2017-02-17 | 2019-09-27 | Hutchinson Fred Cancer Res | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
| WO2019030240A1 (en) | 2017-08-07 | 2019-02-14 | Nbe-Therapeutics Ag | ANTIBODIES BINDING TO A LINEAR HUMAN CS1 EPITOPE |
| BR112020008638A2 (pt) | 2017-11-01 | 2020-10-20 | Juno Therapeutics Inc | receptores de antígenos quiméricos específicos para antígenos de maturação de células b (bcma) |
| AU2018359907A1 (en) | 2017-11-06 | 2020-05-07 | Fred Hutchinson Cancer Center | Combination of a cell therapy and a gamma secretase inhibitor |
| GB201721802D0 (en) | 2017-12-22 | 2018-02-07 | Almac Discovery Ltd | Ror1-specific antigen binding molecules |
| EP3936523A4 (en) * | 2019-01-08 | 2022-09-07 | Shenzhen University | ANTIBODY DETECTION OF MALIGNANT TUMOR CELLS AND THEIR APPLICATIONS |
| MX2021009087A (es) | 2019-01-29 | 2021-09-08 | Juno Therapeutics Inc | Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1). |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| WO2023077026A1 (en) | 2021-10-28 | 2023-05-04 | Lyell Immunopharma, Inc. | Methods for culturing cells expressing ror1-binding protein |
| WO2023186100A1 (zh) * | 2022-04-02 | 2023-10-05 | 山东先声生物制药有限公司 | 抗ror1的抗体及其用途 |
| AU2023313641A1 (en) * | 2022-07-26 | 2025-03-13 | Aimed Bio Inc. | Anti-ror1 antibody and use thereof |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| CN115724973B (zh) * | 2022-09-26 | 2023-07-11 | 普健生物（武汉）科技有限公司 | 抗人ror1高亲和力兔单克隆抗体及其应用 |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| CN115894691A (zh) * | 2022-12-27 | 2023-04-04 | 上海医药集团生物治疗技术有限公司 | 靶向ror1的抗原结合蛋白 |
| CN120476147A (zh) * | 2022-12-27 | 2025-08-12 | 上海医药集团生物治疗技术有限公司 | 靶向ror1的抗原结合蛋白 |
| CN116183472B (zh) * | 2023-04-25 | 2023-08-18 | 上海益诺思生物技术股份有限公司 | Cba法检测非人类灵长类动物细胞因子的验证方法 |
| WO2025007910A1 (en) * | 2023-07-04 | 2025-01-09 | TJ Biopharma (Shanghai) Co., Ltd. | Anti-ror1 antibodies and uses thereof |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA114536A (en) | 1908-09-18 | 1908-10-13 | Adolphe Chalas | Nickel recovering process |
| CA138293A (en) | 1911-11-06 | 1912-02-06 | Charles E. Archie | Variable speed gearing |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| EP2275449B1 (en) | 2000-06-16 | 2016-09-28 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to BLyS |
| CA2480052A1 (en) | 2002-04-01 | 2003-10-16 | Human Genome Sciences, Inc. | Antibodies that specifically bind to gmad |
| WO2005035732A2 (en) | 2003-02-19 | 2005-04-21 | Dyax Corporation | Papp-a ligands |
| CA2762955A1 (en) | 2003-10-16 | 2005-04-28 | Imclone Llc | Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof |
| WO2005097184A2 (en) | 2004-03-26 | 2005-10-20 | Human Genome Sciences, Inc. | Antibodies against nogo receptor |
| MX2011000117A (es) | 2008-07-10 | 2011-02-25 | Toray Industries | Composicion farmaceutica para tratamiento y prevencion de cancer. |
| JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
| CA2759733C (en) | 2009-04-23 | 2019-09-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human ror1 antibodies |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| WO2011159847A2 (en) | 2010-06-15 | 2011-12-22 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof |
| WO2012012695A2 (en) | 2010-07-23 | 2012-01-26 | Fred Hutchinson Cancer Research Center | A method for the treatment of obesity |
| WO2012045085A1 (en) | 2010-10-01 | 2012-04-05 | Oxford Biotherapeutics Ltd. | Anti-rori antibodies |
| US9758586B2 (en) | 2010-12-01 | 2017-09-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric rabbit/human ROR1 antibodies |
| GB201020995D0 (en) | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
| KR101976882B1 (ko) | 2011-03-23 | 2019-05-09 | 프레드 헛친슨 켄서 리서치 센터 | 세포 면역요법용 방법 및 조성물 |
| CA2843960C (en) | 2011-08-09 | 2020-09-15 | Athera Biotechnologies Ab | Antibodies binding to phosphorylcholine (pc) and/or pc conjugates |
| ES2806146T3 (es) | 2011-09-22 | 2021-02-16 | Amgen Inc | Proteínas de unión al antígeno CD27L |
| PL2884999T3 (pl) | 2012-08-20 | 2021-07-05 | Fred Hutchinson Cancer Research Center | Sposób i kompozycje do immunoterapii komórkowej |
| PL3489261T3 (pl) | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| EP2968601A1 (en) | 2013-03-10 | 2016-01-20 | Baylor College Of Medicine | Chemotherapy-resistant immune cells |
| BR112017001821A2 (pt) | 2014-07-29 | 2017-11-21 | Cellectis | receptores de antígenos quiméricos específicos de ror1 (ntrkr1) para imunoterapia de câncer |
| CN107106611B (zh) | 2014-10-27 | 2021-11-23 | 弗雷德哈钦森癌症研究中心 | 用于提高过继细胞免疫疗法效力的组合物和方法 |
| NZ733841A (en) | 2015-01-16 | 2024-01-26 | Juno Therapeutics Inc | Antibodies and chimeric antigen receptors specific for ror1 |
| EP3298032A1 (en) | 2015-05-18 | 2018-03-28 | Bluebird Bio, Inc. | Anti-ror1 chimeric antigen receptors |
| CN108699149B (zh) | 2016-02-02 | 2023-01-06 | 弗雷德哈钦森癌症中心 | 抗-ror1抗体及其用途 |
| MA45341A (fr) | 2016-06-06 | 2019-04-10 | Hutchinson Fred Cancer Res | Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive |
-
2017
- 2017-02-02 CN CN201780009313.5A patent/CN108699149B/zh active Active
- 2017-02-02 JP JP2018539977A patent/JP7029401B2/ja active Active
- 2017-02-02 WO PCT/US2017/016300 patent/WO2017136607A1/en not_active Ceased
- 2017-02-02 AU AU2017213844A patent/AU2017213844A1/en not_active Abandoned
- 2017-02-02 ES ES17705745T patent/ES2903228T3/es active Active
- 2017-02-02 EP EP17705745.2A patent/EP3411408B1/en active Active
- 2017-02-02 MX MX2018009011A patent/MX2018009011A/es unknown
- 2017-02-02 EP EP21204990.2A patent/EP4006056A1/en active Pending
- 2017-02-02 CA CA3012827A patent/CA3012827A1/en active Pending
- 2017-02-02 US US16/074,737 patent/US10968275B2/en active Active
-
2021
- 2021-01-25 US US17/157,810 patent/US11932691B2/en active Active
- 2021-12-02 JP JP2021196080A patent/JP2022028918A/ja active Pending
-
2024
- 2024-02-07 US US18/435,933 patent/US20240352119A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022028918A5 (enExample) | ||
| JP2019511904A5 (enExample) | ||
| DK2900265T3 (en) | Anti-Uroplakin II Antibodies, Systems and Methods | |
| JP6244912B2 (ja) | 癌の検出方法 | |
| EP3052522B1 (en) | Anti-sox10 antibody systems and methods | |
| CN102687011B (zh) | 癌症生物标志物及其应用 | |
| EP2962113B1 (en) | Anti-p40 antibodies systems and methods | |
| JP6244911B2 (ja) | 癌の検出方法 | |
| JP5669757B2 (ja) | 精巣癌診断および予後診断におけるｒｂｍ３タンパク質 | |
| EP4010706A1 (en) | Clinical management of oropharyngeal squamous cell carcinoma | |
| CN103238069B (zh) | 肺癌和结直肠癌中的bard1同工型及其应用 | |
| US9416176B2 (en) | RBM3 protein in colorectal cancer prognostics | |
| CN105849565A (zh) | Shon作为癌症预后生物标志物并预测癌症内分泌治疗的疗效 | |
| KR20070073802A (ko) | Ｗｎｔ 단백질 및 암의 검출 및 치료 | |
| JP2012501440A (ja) | 内分泌処置予測因子としてのａｎｌｎタンパク質 | |
| CN101302254A (zh) | 抗肝癌源性生长因子单克隆抗体及其应用 | |
| EP3203238A1 (en) | Reagents for detecting or diagnosing cancer cells having high invasive capacity | |
| US20160108477A1 (en) | Traceability of Cellular Cycle Anomalies Targeting Oncology and Neurodegeneration | |
| JP2021503289A (ja) | 新規なｃｉｐ２ａバリアント及びその使用 | |
| JP6695586B2 (ja) | 膵癌の再発リスクの予測に用いるための診断薬及びキット、並びに予測方法 | |
| CN108467433B (zh) | 抗Napsin A蛋白的单克隆抗体及其细胞株、制备方法和应用 | |
| WO2020225547A1 (en) | Methods of determining the margin of a tumour | |
| US20240376227A1 (en) | ANTI-CK2a ANTIBODY OR A FRAGMENT THEREOF | |
| US20180223372A1 (en) | Identification of predictive biomarkers associated with wnt pathway inhibitors | |
| CN109021100B (zh) | 特异性识别fsd1蛋白的单克隆抗体 |